Funding Received
$112.5 Million in 3 Rounds from 1 Investor
Most Recent Funding
$105 Million Series D on April 15, 2014
Seattle, WA
Adaptive Biotechnologies offers research and diagnostic tools for scientists and clinicians involved in genomic immunology.
Chad Robins, Christopher Carlson, Harlan Robins
Health Care, Bio-Pharm, Biotechnology

Company Details


Adaptive Biotechnologies Corporation (, headquartered in Seattle, WA, is pioneering the field of genomic immunology. The company’s core competency is developing next generation sequencing assays that characterize the adaptive immune system, serving as a platform technology to the research community and the biopharmaceutical industry. Its flagship commercial product, immunoSEQ (, uses a proprietary immune profiling assay to analyze T cells and B cells – critical components of the adaptive immune system’s defense against disease – with unprecedented depth and specificity. Sequencing the variable region of these immune cells allows researchers to characterize the complete immune repertoire of a patient or group of patients in search of immunologic biomarkers. Fueled by discoveries from immunoSEQ, the company is currently developing a pipeline of clinical assays that are specific to cancer diagnosis and prognosis. All of Adaptive Biotechnologies’ assays are coupled with a cloud-computing infrastructure that simplifies the interpretation of massive quantities of data in a user-friendly interface. immunoSEQ was launched in September 2010 and has a worldwide customer base.

Current Team (10)


Funding Rounds (3) - $112.5M


Board Members and Advisors (15)


Offices/Locations (1)

  • Office

    1551 Eastlake Ave E

    Suite 200

    Seattle, WA 98102


Images (3)

  • Uwymliljb7xyjrnzqvpe
  • Putiuzvnruha0jehzc1g
  • 4c4351b273d4b3f505021923b7bc1440